LENZ - NASDAQ
LENZ Therapeutics, Inc.
$7.01
-0.14%LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
At a Glance
Live SnapshotLENZ Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
LENZ Therapeutics, Inc. Income Statement
LENZ • NASDAQ
| LENZ Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
19.1M | 0.0 | 0.0 | 15M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(418K) | (58K) | (0.0) | (0.0) | (734K) | (121K) | (0.0) | |
18.7M | -58K | 0.0 | 15M | -734K | -121K | 0.0 | |
OPERATING INCOME | |||||||
(109.8M) | (58.6M) | (72.4M) | (25.5M) | (59.7M) | (13.4M) | (29K) | |
(91.1M) | (28.8M) | (12.9M) | (4.4M) | (21.8M) | (4.3M) | (29K) | |
(18.7M) | (29.8M) | (59.5M) | (21.1M) | (37.9M) | (9.1M) | (0.0) | |
-91.1M | -58.6M | -72.4M | -10.5M | -60.4M | -13.5M | -29K | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (40K) | (80K) | |
9.8M | 8.6M | 2.2M | 0.0 | 0.0 | -40K | -80K | |
9.5M | 8.8M | 2.3M | 19K | -10.3M | -54.9M | -80K | |
-81.6M | -49.8M | -70.1M | -10.5M | -70.8M | -68.4M | -109K | |
NET INCOME | |||||||
(502K) | (1K) | -179K | (347K) | (0.0) | (0.0) | (0.0) | |
-82.1M | -49.8M | -70M | -10.8M | -70.8M | -68.4M | -109K |
SEC Filings
LENZ - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 12, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 08, 2025 | October 08, 2025 | 2025 |
Related Guides
Continue your LENZ research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.